Ophthalmology News

BARCELONA, Spain — In this Healio Video Perspective from the European Society of Cataract and Refractive Surgeons meeting, Pavel Stodulka, MD, PhD, discusses the Perfect Lens procedure.

Oral gildeuretinol acetate did not meet the primary endpoint of geographic atrophy lesion growth rate in a phase 3 study, according to a press release from Alkeus Pharmaceuticals.

Avacincaptad pegol may help postpone driving restrictions or loss of driving eligibility in patients with geographic atrophy, according to a post hoc analysis of the GATHER1 and GATHER2 trials.

On this episode, Laura Enyedi, MD, is live from the Women in Ophthalmology meeting with Pratap Challa, MD, Fasika Woreta, MD, Jennifer Lindsey, MD, and Annie Wishna, MD, discussing residency programs.

According to a new report from the National Academies of Sciences, Engineering and Medicine, more consistent international data are necessary to fully understand myopia and its underlying mechanisms.

ATSN-201 received orphan drug designation from the FDA for the treatment of X-linked retinoschisis, according to a press release from Atsena Therapeutics.

ANI Pharmaceuticals finalized its acquisition of Alimera Sciences, according to a press release.

BARCELONA, Spain — In this Healio Video Perspective from the European Society of Cataract and Refractive Surgeons meeting, Richard Lewis, MD, speaks about femtosecond laser image-guided high-precision trabeculotomy, or FLigHT.

While there are currently no FDA-approved pharmacological therapies for the treatment of cataracts, an eye drop demonstrated promising vision improvements in patients with early-stage cataracts in a phase 1/2 clinical trial.

In this video, Barbara Blodi, MD, discusses long-term data on geographic atrophy growth rates in treatment-naive patients with age-related macular degeneration.